Linkthera's Zemprocitinib Meets Primary Endpoint in Phase 3 COURAGE-RA Trial
Start here
Linkthera's zemprocitinib met the primary and key secondary endpoints at week 24 in the phase 3 COURAGE-RA study, with p<0.0001, in patients with moderate-to-severe active rheumatoid arthritis who had an inadequate response to biologic DMARDs. The study randomized 430 patients, 429 of whom received at least one dose. Among patients continuing treatment, response rates were durable: ACR20, ACR50 and ACR70 were 93.0%, 79.9% and 52.5% at week 52, and 91.8%, 80.5% and 62.4% at week 76. Results were announced on 28 October 2026. What remains open is fuller reporting of the safety and secondary endpoint data, and any filing or approval steps for this indication.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- mp.weixin.qq.comPickLinkthera's Zemprocitinib Hits Primary Endpoint in Phase 3 COURAGE-RA in RA Patients with Inadequate bDMARD Response, Efficacy Maintained to Week 76
Linkthera announced that zemprocitinib met the primary and key secondary endpoints at week 24 in a phase 3 study of patients with moderate-to-severe active RA and inadequate response to bDMARDs (p<0.0001). The COURAGE-RA study randomized 430 patients, of whom 429 received at least one dose. Among patients continuing treatment, ACR20, ACR50 and ACR70 response rates were 93.0%, 79.9% and 52.5% at week 52, and 91.8%, 80.5% and 62.4% at week 76.
Heat trend for this story
Heat now 8·Peak in the comparable set 10 (Oct 28 09:00)·Change over 24h in the comparable set –·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.